Publication date: Aug 07, 2024
The researchers are also seeking to further advance the study of the INT in non-small cell lung cancer, renal cell carcinoma, urothelial carcinoma, and cutaneous squamous cell carcinoma. Such immunotherapies have become increasingly important in treating cancer and may be used alongside INTs to further increase the immune system’s ability to stage a long-lasting response to cancer. However, success has been limited due to the technological challenge of engineering therapies that provide specific enough -training” to the immune system to identify a given patient’s neoantigens. -We showed that this INT was able to generate new immune responses against neoantigens, and it appeared that those immune responses were maintained at later time points. The FDA granted a breakthrough therapy designation to the study of mRNA-4157 (V940) with pembrolizumab for melanoma treatment, which can help expedite the development and review of the treatment. The potential for a precise, durable immune response is one of the most exciting aspects of therapies like this one. -While it may sound like science fiction, we’ve shown that we can develop an individualized neoantigen therapy by leveraging the specific characteristics of a given patient’s tumor and cell-type.
Concepts | Keywords |
---|---|
American | Brigham |
Cancer | Care |
Harvard | General |
Nct03313778 | Immune |
Teaching | Individualized |
Mass | |
Merck | |
Mrna | |
Neoantigens | |
Patients | |
System | |
Therapies | |
Therapy | |
Treatment | |
V940 |
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | renal cell carcinoma |
pathway | KEGG | Renal cell carcinoma |
disease | MESH | carcinoma |
disease | MESH | squamous cell carcinoma |
pathway | KEGG | Melanoma |
disease | MESH | melanoma |
disease | MESH | Cancer |
drug | DRUGBANK | Pembrolizumab |
disease | MESH | causes |
disease | MESH | lost to follow-up |
pathway | KEGG | Non-small cell lung cancer |
disease | MESH | non-small cell lung cancer |
drug | DRUGBANK | Spinosad |
disease | MESH | lung cancer |
pathway | REACTOME | Immune System |